Wall Street analysts predict that Seres Therapeutics, Inc. (NASDAQ:MCRB) will post sales of $18.01 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Seres Therapeutics’ earnings, with the highest sales estimate coming in at $23.02 million and the lowest estimate coming in at $3.00 million. Seres Therapeutics posted sales of $13.02 million in the same quarter last year, which indicates a positive year over year growth rate of 38.3%. The firm is expected to report its next quarterly earnings report on Thursday, November 9th.

According to Zacks, analysts expect that Seres Therapeutics will report full-year sales of $18.01 million for the current financial year, with estimates ranging from $12.00 million to $32.00 million. For the next financial year, analysts expect that the company will report sales of $20.62 million per share, with estimates ranging from $12.00 million to $31.40 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Seres Therapeutics.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.59) by ($0.10). Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million. During the same period in the previous year, the business posted ($0.70) earnings per share. The company’s revenue for the quarter was up .0% on a year-over-year basis.

MCRB has been the topic of a number of research reports. Zacks Investment Research raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Wednesday, July 5th. BidaskClub raised shares of Seres Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. ValuEngine raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Canaccord Genuity set a $20.00 target price on shares of Seres Therapeutics and gave the stock a “buy” rating in a report on Thursday, August 3rd. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price target (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company. Seres Therapeutics has an average rating of “Buy” and an average price target of $18.00.

WARNING: This report was originally posted by American Banking News and is owned by of American Banking News. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/10/18/18-01-million-in-sales-expected-for-seres-therapeutics-inc-mcrb-this-quarter.html.

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Seres Therapeutics by 1.2% during the second quarter. Vanguard Group Inc. now owns 1,585,026 shares of the biotechnology company’s stock worth $17,911,000 after acquiring an additional 19,363 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Seres Therapeutics by 21.5% during the second quarter. ARK Investment Management LLC now owns 765,191 shares of the biotechnology company’s stock worth $8,647,000 after acquiring an additional 135,276 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Seres Therapeutics by 15.9% during the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock worth $4,172,000 after acquiring an additional 50,860 shares during the last quarter. State Street Corp grew its position in shares of Seres Therapeutics by 12.0% during the second quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock worth $3,637,000 after acquiring an additional 34,393 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Seres Therapeutics by 16.2% during the second quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock worth $2,664,000 after acquiring an additional 32,875 shares during the last quarter. Institutional investors and hedge funds own 74.76% of the company’s stock.

Seres Therapeutics (NASDAQ:MCRB) opened at 10.93 on Wednesday. The stock’s market capitalization is $442.80 million. Seres Therapeutics has a 12 month low of $8.85 and a 12 month high of $17.42. The firm’s 50-day moving average is $14.07 and its 200 day moving average is $14.07.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.